Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension

Masaru Hatano, Hidehiro Yamada, Keiichi Fukuda, Koichiro Yoshioka, Masanori Funauchi, Masataka Kuwana, Masataka Sata, Mitsugu Taniguchi, Norifumi Nakanishi, Takefumi Saito, Tsutomu Saji, Shigetake Sasayama

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) trial has mostly enrolled patients with World Health Organization functional class (WHO FC) III or IV. However, PAH is rapidly progressive in nature even in patients with less severe forms at diagnosis. Following the recent studies in Western population, here we assessed the efficacy of bosentan in Japanese patients with WHO FCII PAH. In this open-label trial, bosentan 125 mg twice daily was administered for 12 weeks in 16 patients, and a hemodynamic evaluation was performed. Treatment was continued for a further 12 weeks, where the effect on exercise capacity was assessed in 13 patients. In 16 patients, mean pulmonary arterial pressure decreased from 40.4 ± 10.4 to 35.6 ± 12.6 mmHg (p = 0.018) and cardiac index increased from 2.54 ± 0.73 to 2.96 ± 0.82 L/min/m2 (p = 0.023). Thus, pulmonary vascular resistance decreased from 792 ± 565 to 598 ± 558 dyn·sec/cm5 (p = 0.006). In 13 patients followed up for 24 weeks, 6-min walking distance increased from baseline at Week 12 (p = 0.003) and Week 24 (p = 0.011). All patients were mildly symptomatic at baseline with dyspnea index (Borg scale) of 2.50 ± 1.58 and the specific activity scale (SAS) of 5.0 ± 1.4 METs. These values remained unchanged throughout the study. These results suggest that bosentan treatment was beneficial for Japanese patients with WHO FC II PAH and treatment should be started in the early stage of the disease.

Original languageEnglish
Pages (from-to)798-804
Number of pages7
JournalHeart and Vessels
Volume30
Issue number6
DOIs
Publication statusPublished - 2015 Nov 1

Fingerprint

Pulmonary Hypertension
Hemodynamics
Exercise
Endothelin Receptor Antagonists
bosentan
Vascular Resistance
Dyspnea
Walking
Arterial Pressure
Therapeutics
Lung
Population

Keywords

  • Bosentan
  • Endothelin receptor antagonist
  • Hemodynamics
  • Pulmonary arterial hypertension
  • World Health Organization functional class

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension. / Hatano, Masaru; Yamada, Hidehiro; Fukuda, Keiichi; Yoshioka, Koichiro; Funauchi, Masanori; Kuwana, Masataka; Sata, Masataka; Taniguchi, Mitsugu; Nakanishi, Norifumi; Saito, Takefumi; Saji, Tsutomu; Sasayama, Shigetake.

In: Heart and Vessels, Vol. 30, No. 6, 01.11.2015, p. 798-804.

Research output: Contribution to journalArticle

Hatano, M, Yamada, H, Fukuda, K, Yoshioka, K, Funauchi, M, Kuwana, M, Sata, M, Taniguchi, M, Nakanishi, N, Saito, T, Saji, T & Sasayama, S 2015, 'Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension', Heart and Vessels, vol. 30, no. 6, pp. 798-804. https://doi.org/10.1007/s00380-014-0544-1
Hatano, Masaru ; Yamada, Hidehiro ; Fukuda, Keiichi ; Yoshioka, Koichiro ; Funauchi, Masanori ; Kuwana, Masataka ; Sata, Masataka ; Taniguchi, Mitsugu ; Nakanishi, Norifumi ; Saito, Takefumi ; Saji, Tsutomu ; Sasayama, Shigetake. / Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension. In: Heart and Vessels. 2015 ; Vol. 30, No. 6. pp. 798-804.
@article{76f717e9509e4a3ca23f063a1bfb7e84,
title = "Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension",
abstract = "Pulmonary arterial hypertension (PAH) trial has mostly enrolled patients with World Health Organization functional class (WHO FC) III or IV. However, PAH is rapidly progressive in nature even in patients with less severe forms at diagnosis. Following the recent studies in Western population, here we assessed the efficacy of bosentan in Japanese patients with WHO FCII PAH. In this open-label trial, bosentan 125 mg twice daily was administered for 12 weeks in 16 patients, and a hemodynamic evaluation was performed. Treatment was continued for a further 12 weeks, where the effect on exercise capacity was assessed in 13 patients. In 16 patients, mean pulmonary arterial pressure decreased from 40.4 ± 10.4 to 35.6 ± 12.6 mmHg (p = 0.018) and cardiac index increased from 2.54 ± 0.73 to 2.96 ± 0.82 L/min/m2 (p = 0.023). Thus, pulmonary vascular resistance decreased from 792 ± 565 to 598 ± 558 dyn·sec/cm5 (p = 0.006). In 13 patients followed up for 24 weeks, 6-min walking distance increased from baseline at Week 12 (p = 0.003) and Week 24 (p = 0.011). All patients were mildly symptomatic at baseline with dyspnea index (Borg scale) of 2.50 ± 1.58 and the specific activity scale (SAS) of 5.0 ± 1.4 METs. These values remained unchanged throughout the study. These results suggest that bosentan treatment was beneficial for Japanese patients with WHO FC II PAH and treatment should be started in the early stage of the disease.",
keywords = "Bosentan, Endothelin receptor antagonist, Hemodynamics, Pulmonary arterial hypertension, World Health Organization functional class",
author = "Masaru Hatano and Hidehiro Yamada and Keiichi Fukuda and Koichiro Yoshioka and Masanori Funauchi and Masataka Kuwana and Masataka Sata and Mitsugu Taniguchi and Norifumi Nakanishi and Takefumi Saito and Tsutomu Saji and Shigetake Sasayama",
year = "2015",
month = "11",
day = "1",
doi = "10.1007/s00380-014-0544-1",
language = "English",
volume = "30",
pages = "798--804",
journal = "Heart and Vessels",
issn = "0910-8327",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension

AU - Hatano, Masaru

AU - Yamada, Hidehiro

AU - Fukuda, Keiichi

AU - Yoshioka, Koichiro

AU - Funauchi, Masanori

AU - Kuwana, Masataka

AU - Sata, Masataka

AU - Taniguchi, Mitsugu

AU - Nakanishi, Norifumi

AU - Saito, Takefumi

AU - Saji, Tsutomu

AU - Sasayama, Shigetake

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Pulmonary arterial hypertension (PAH) trial has mostly enrolled patients with World Health Organization functional class (WHO FC) III or IV. However, PAH is rapidly progressive in nature even in patients with less severe forms at diagnosis. Following the recent studies in Western population, here we assessed the efficacy of bosentan in Japanese patients with WHO FCII PAH. In this open-label trial, bosentan 125 mg twice daily was administered for 12 weeks in 16 patients, and a hemodynamic evaluation was performed. Treatment was continued for a further 12 weeks, where the effect on exercise capacity was assessed in 13 patients. In 16 patients, mean pulmonary arterial pressure decreased from 40.4 ± 10.4 to 35.6 ± 12.6 mmHg (p = 0.018) and cardiac index increased from 2.54 ± 0.73 to 2.96 ± 0.82 L/min/m2 (p = 0.023). Thus, pulmonary vascular resistance decreased from 792 ± 565 to 598 ± 558 dyn·sec/cm5 (p = 0.006). In 13 patients followed up for 24 weeks, 6-min walking distance increased from baseline at Week 12 (p = 0.003) and Week 24 (p = 0.011). All patients were mildly symptomatic at baseline with dyspnea index (Borg scale) of 2.50 ± 1.58 and the specific activity scale (SAS) of 5.0 ± 1.4 METs. These values remained unchanged throughout the study. These results suggest that bosentan treatment was beneficial for Japanese patients with WHO FC II PAH and treatment should be started in the early stage of the disease.

AB - Pulmonary arterial hypertension (PAH) trial has mostly enrolled patients with World Health Organization functional class (WHO FC) III or IV. However, PAH is rapidly progressive in nature even in patients with less severe forms at diagnosis. Following the recent studies in Western population, here we assessed the efficacy of bosentan in Japanese patients with WHO FCII PAH. In this open-label trial, bosentan 125 mg twice daily was administered for 12 weeks in 16 patients, and a hemodynamic evaluation was performed. Treatment was continued for a further 12 weeks, where the effect on exercise capacity was assessed in 13 patients. In 16 patients, mean pulmonary arterial pressure decreased from 40.4 ± 10.4 to 35.6 ± 12.6 mmHg (p = 0.018) and cardiac index increased from 2.54 ± 0.73 to 2.96 ± 0.82 L/min/m2 (p = 0.023). Thus, pulmonary vascular resistance decreased from 792 ± 565 to 598 ± 558 dyn·sec/cm5 (p = 0.006). In 13 patients followed up for 24 weeks, 6-min walking distance increased from baseline at Week 12 (p = 0.003) and Week 24 (p = 0.011). All patients were mildly symptomatic at baseline with dyspnea index (Borg scale) of 2.50 ± 1.58 and the specific activity scale (SAS) of 5.0 ± 1.4 METs. These values remained unchanged throughout the study. These results suggest that bosentan treatment was beneficial for Japanese patients with WHO FC II PAH and treatment should be started in the early stage of the disease.

KW - Bosentan

KW - Endothelin receptor antagonist

KW - Hemodynamics

KW - Pulmonary arterial hypertension

KW - World Health Organization functional class

UR - http://www.scopus.com/inward/record.url?scp=84947493138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947493138&partnerID=8YFLogxK

U2 - 10.1007/s00380-014-0544-1

DO - 10.1007/s00380-014-0544-1

M3 - Article

C2 - 25028167

AN - SCOPUS:84947493138

VL - 30

SP - 798

EP - 804

JO - Heart and Vessels

JF - Heart and Vessels

SN - 0910-8327

IS - 6

ER -